title: Prognostic significance of overexpression of EZH2 and H3k27me3 proteins in gastric cancer.
abstract: The enhancer of zeste homolog 2 (EZH2) methyl transferase and histone 3 lysine 27 (H3K27me3) protein can repress gene transcription, and their aberrant expression has been observed in various human cancers. This study determined their expression levels in gastric cancer tissues with reference to clinicopathological features and patient survival. We collected 117 gastric cancer and corresponding normal tissues for immunohistochemistry analysis. In gastric cancers, 82/117 (70.1%) were positive for EZH2 and 66/117 (56.4%) for H3K27me3 proteins in contrast to only 5.41% and 7.25% of normal gastric mucosa specimens, respectively. Kaplan-Meier survival data showed the average overall and disease-free survival of EZH2 high expression patients was 25.2 and 20.2 months, respectively, shorter than that with EZH2 low expression (40.5 and 35.9 months). The average overall survival and disease-free survival of high H3K27me3 expression patients was 23.4 and 17.4 months, shorter than without H3K27me3 expression (37.6 and 34.5 months). The average overall survival and disease-free survival of patients with both EZH2 and H3K27me3 expression was 18.8 and 12.9 months, respectively, shorter than that with either alone (34.7 and 31.2 months) or with low levels of both (43.9 and 39.9 months). Multivariate Cox regression analysis showed that H3K27me3 and EZH2 expression, tumor size differentiation and clinical stage were all independent prognostic factors for predicting patient survival. This study demonstrated that detection of both EZH2 and H3K27me3 proteins can predict poor survival of gastric cancer patients, superior to single protein detection. In addition, H3K27me3 and EZH2 protein expression could predict lymph node metastasis.
authors.affiliation: The State Key Laboratory of Oncology in South China, Sun Yat-sen University, Guangzhou, China.
authors.forename: Long-Jun
authors.initials: LJ
authors.lastname: He
authors.forename: Mu-Yan
authors.initials: MY
authors.lastname: Cai
authors.forename: Guo-Liang
authors.initials: GL
authors.lastname: Xu
authors.forename: Jian-Jun
authors.initials: JJ
authors.lastname: Li
authors.forename: Zi-Jin
authors.initials: ZJ
authors.lastname: Weng
authors.forename: Da-Zhi
authors.initials: DZ
authors.lastname: Xu
authors.forename: Guang-Yu
authors.initials: GY
authors.lastname: Luo
authors.forename: Sen-Lin
authors.initials: SL
authors.lastname: Zhu
authors.forename: Dan
authors.initials: D
authors.lastname: Xie
mesh_terms: D018572:Disease-Free Survival; D000071221:Enhancer of Zeste Homolog 2 Protein; D005260:Female; D005500:Follow-Up Studies; D006657:Histones / Q000096:biosynthesis* / Q000378:metabolism; D006801:Humans; D007150:Immunohistochemistry / Q000379:methods; D008239:Lysine / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D063151:Polycomb Repressive Complex 2 / Q000096:biosynthesis* / Q000235:genetics; D011379:Prognosis; D012044:Regression Analysis; D012189:Retrospective Studies; D013274:Stomach Neoplasms / Q000235:genetics / Q000378:metabolism* / Q000473:pathology
chemical_list: D006657:Histones; C498409:EZH2 protein, human; D000071221:Enhancer of Zeste Homolog 2 Protein; D063151:Polycomb Repressive Complex 2; D008239:Lysine